TrialInternational journal of hematology2024

Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.

Yosuke Minami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.